Probing Medin Monomer Structure and its Amyloid Nucleation Using 13C-Direct Detection NMR in Combination with

Hannah A Davies1, Daniel J Rigden1, Marie M Phelan1

  • 1Institute of Integrative Biology, University of Liverpool, Biosciences Building, Crown Street, L69 7ZB, UK.

Scientific Reports
|March 23, 2017
PubMed

Insights

Aortic medial amyloid, caused by medin protein deposition, is common but poorly understood. New research models soluble medin, revealing a potential nucleation pathway for amyloid fibril formation.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Biophysics

Background:

  • Aortic medial amyloid is the most prevalent form of amyloidosis.
  • It involves the deposition of the medin protein in the medial layer of arteries.
  • Little is currently known about the structure and formation mechanism of medin.

Purpose of the Study:

  • To elucidate the structure of soluble monomeric medin.
  • To investigate the molecular mechanism of medin amyloid nucleation and fibril formation.

Main Methods:

  • Ab initio protein modeling was used to generate a structural model for soluble medin.
  • Carbon-13 direct detection Nuclear Magnetic Resonance (NMR) spectroscopy provided experimental structural data.
  • Molecular dynamics simulations were employed to study the protein's conformational changes and interactions.

Main Results:

  • A stable core of three beta-strands with labile terminal strands was identified in soluble monomeric medin.
  • Molecular dynamics simulations indicated that C-terminal strand detachment exposes amyloidogenic regions.
  • This exposure facilitates dimerisation and subsequent fibril formation, suggesting a nucleation pathway.

Conclusions:

  • The study provides a structural model for soluble medin and proposes a novel nucleation mechanism for aortic medial amyloid formation.
  • This mechanism, involving the exposure of amyloidogenic regions upon conformational change, may be shared by other amyloidogenic proteins.
  • Understanding this pathway is crucial for future therapeutic strategies targeting amyloid deposition in arteries.